Skip to main content
Premium Trial:

Request an Annual Quote

Bayer Diagnostics, Innogenetics

Premium
Bayer Diagnostics and Innogenetics have launched their jointly developed Versant HCV Genotype 2.0 assay for hepatitis C virus genotyping. The assay is an upgrade of Bayer’s Versant HCV Genotype 1.0 Assay and is now available for sale in Europe.
 
In addition to its ability to accurately classify HCV genotypes 1 to 6, the assay now also provides “accurate identification of genotypes 6c-l (formerly known as genotypes 7, 8, and 9) and improves the identification of genotype 1a and 1b,” the companies said in a statement.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.